← All trials
NCT04995653
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2021
- Primary completion
- May 31, 2025
- Completion date
- May 31, 2025
- First posted
- Aug 9, 2021
- Last posted
- Sep 22, 2021
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Seres TherapeuticsLead sponsor
- Seres TherapeuticsStudy director
- Memorial Sloan-Kettering Cancer CenterCollaborator
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.